Bivalent GAD autoantibody ELISA improves clinical utility and risk prediction for adult autoimmune diabetes
Journal of Diabetes Investigation · 2023
DOI: 10.1111/jdi.13980 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetes Investigation, 2023. Verfasst von Eiji Kawasaki und 19 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Center, Shin-Koga Hospital, Kurume, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim/Introduction To investigate the differences in the clinical significance and glutamic acid decarboxylase autoantibody (GADA) affinity between RIA (RIA‐GADA) and ELISA (ELISA‐GADA) in patients with type 1 diabetes.
Methods
A total of 415 patients with type 1 diabetes were enrolled, including 199 acute‐onset type 1 diabetes, 168 slowly progressive type 1 diabetes (SPIDDM), and 48 fulminant type 1 diabetes. GADA affinity was measured by a competitive binding experiment using unlabeled recombinant human GAD65 protein, and the diagnostic performance of both assays and the relationship between GADA affinity and the decline of fasting C‐peptide (F‐CPR) were examined.
Results
While the ELISA‐GADA displayed a higher sensitivity than the RIA method in diagnosing type 1 diabetes in acute‐onset patients, about 40% of SPIDDM patients with low‐titer RIA‐GADA were determined as negative by the ELISA method. Patients with type 1 diabetes with RIA‐GADA alone had an older age of onset, less diabetic ketoacidosis, a higher BMI, and a higher F‐CPR compared with patients positive for both RIA‐GADA and ELISA‐GADA. Additionally, 36% of RIA‐GADA‐positive patients had low‐affinity GADA (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Diabetes Center, Shin-Koga Hospital, Kurume, Japan.
- Department of Endocrinology and Diabetes, School of Medicine, Saitama Medical University, Iruma, Japan.
- Department of Internal Medicine (I), Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
- Department of Endocrinology and Metabolism, Nagasaki University Hospital, Nagasaki, Japan.
- Pancreatic Islet Cell Transplantation Center, National Center for Global Health and Medicine, Tokyo, Japan.
- Department of Diabetes and Molecular Genetics, Ehime University Graduate School of Medicine, Toon, Japan.
ORCID-Profile: Eiji Kawasaki, Akira Shimada, Akihisa Imagawa, Yoichi Oikawa, Junji Kozawa, Tetsuro Kobayashi, Tomoyasu Fukui, Junnosuke Miura, Hiroshi Ikegami
Zitieren
APA
Kawasaki, E., Shimada, A., Imagawa, A., Abiru, N., Awata, T., Oikawa, Y., Osawa, H., Kawabata, Y., Kozawa, J., Kobayashi, T., Takahashi, K., Chujo, D., Fukui, T., Miura, J., Yasuda, K., Yasuda, H., Kajio, H., Hanafusa, T., Ikegami, H., & Committee of type 1 diabetes, Japan Diabetes Society (2023). Bivalent GAD autoantibody ELISA improves clinical utility and risk prediction for adult autoimmune diabetes. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.13980
Vancouver
Kawasaki E, Shimada A, Imagawa A, Abiru N, Awata T, Oikawa Y, et al. Bivalent GAD autoantibody ELISA improves clinical utility and risk prediction for adult autoimmune diabetes. Journal of Diabetes Investigation. 2023. doi:10.1111/jdi.13980
BibTeX
@article{Kawasaki2023,
author = {Kawasaki, Eiji and Shimada, Akira and Imagawa, Akihisa and Abiru, Norio and Awata, Takuya and Oikawa, Yoichi and Osawa, Haruhiko and Kawabata, Yumiko and Kozawa, Junji and Kobayashi, Tetsuro and Takahashi, Kazuma and Chujo, Daisuke and Fukui, Tomoyasu and Miura, Junnosuke and Yasuda, Kazuki and Yasuda, Hisafumi and Kajio, Hiroshi and Hanafusa, Toshiaki and Ikegami, Hiroshi and Committee of type 1 diabetes, Japan Diabetes Society, Committee of type 1 diabetes, Japan Diabetes Society},
title = {Bivalent GAD autoantibody ELISA improves clinical utility and risk prediction for adult autoimmune diabetes},
journal = {Journal of Diabetes Investigation},
year = {2023},
doi = {10.1111/jdi.13980}
}
EUVIMED